Menu

Immuno-Oncology for Solid Tumors: Overcoming Barriers in the Tumor Microenvironment

The Scientist is bringing together a panel of experts to share their research and insights into what it may take to overcome the barriers in the tumor microenvironment.

May 28, 2019
The Scientist Creative Services Team

FREE Webinar

Tuesday, June 18, 2019
2:30-4:00 PM Eastern Time
Register Now

The solid tumor microenvironment is immunosuppressive and poses a significant obstacle to achieving clinical success with various immunotherapies. Most notably, immune checkpoint pathways, including PD-1, PD-L1, and CTLA-4, allow tumors to evade the body’s usual immune reaction, leading to disease progression. Checkpoint blockade via monoclonal antibodies results in augmented T-cell activation and proliferation to enhance the anti-tumor immune response and has revolutionized the field, but not all patients are candidates and severe adverse effects persist. Therefore, the development of other approaches, such as antibody-drug conjugates, vaccines, and adoptive cell-based therapies, has surged. Recent advances in immunotherapy have certainly produced enhanced treatment options for solid tumors, but obstacles to their mainstream use remain. To explore novel strategies in immuno-oncology for solid tumors, The Scientist is bringing together a panel of experts to share their research and insights into what it may take to overcome the barriers in the tumor microenvironment.

Topics to be covered:

  • Immunotherapy in Lung Cancer
  • Adoptive Immunotherapy: Overcoming Barriers Against Solid Tumors with Potent T cells

Register Now

Meet the Speakers:

Grace Dy, MD
Chief, Thoracic Oncology
Associate Professor of Oncology
Department of Medicine
                          Roswell Park Comprehensive Cancer Center

Chrystal Paulos, PhD
Associate Professor of Microbiology and Immunology
Co-Leader of the Cancer Immunology Program at the Hollings Cancer Center
Endowed Peng Chair of Melanoma in Department of Dermatology and Dermatological Surgery
                          Medical University of South Carolina, College of Medicine

 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.